Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product

Barr Laboratories, Inc. and Galen Holdings PLC have announced that they have signed a letter of intent for Barr to acquire the exclusive rights in the United States and Canada for Loestrin(R) and Loestrin(R) FE oral contraceptive products. The proposed transaction also would include a settlement of pending litigation between Barr and Galen regarding Galen’s Read more about Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product[…]

Lannett Company, Inc. And Spectrum Pharmaceuticals, Inc. Announce Ciprofloxacin Joint Venture

Lannett Company, Inc., a generic pharmaceutical manufacturer, and Spectrum Pharmaceuticals, Inc., have announced an agreement for the manufacturing, supply, distribution and marketing of Ciprofloxacin tablets. Arthur Bedrosian, Lannett’s President, said, “We are excited about the opportunity to work with Spectrum on this venture. With a talented scientific staff, Spectrum has an excellent future in the Read more about Lannett Company, Inc. And Spectrum Pharmaceuticals, Inc. Announce Ciprofloxacin Joint Venture[…]

Dendreon Corporation Completes Acquisition Of Corvas International

Dendreon Corporation has announced that it has completed its acquisition of Corvas International. The acquisition provides Dendreon with an enhanced product pipeline and the financial position to discover, develop and commercialize innovative therapeutic products in oncology. “This is a very exciting time for Dendreon, our stockholders and the many cancer patients who could potentially benefit Read more about Dendreon Corporation Completes Acquisition Of Corvas International[…]

Skyepharma Begins Requip Ocr Clinical

Skyepharma has initiated Phase III clinical trials of the oral controlled release formulation of GlaxoSmithKline‘s Requip (Ropinirole HCl). The new once daily formulation for Parkinson’s disease has been developed utilizing SkyePharma’s Geomatrix technology. Requip OCR is expected to simplify the treatment regime for patients using this drug, thus improving patient convenience and compliance. The company Read more about Skyepharma Begins Requip Ocr Clinical[…]

Schering, Philogen Agree License Deal

Schering AG, and Philogen S.r.l., have announced that Schering acquired exclusive worldwide development and marketing rights for an antibody-based therapeutic fusion protein from Philogen. It is expected to have the potential to treat solid tumors by triggering immunological mechanisms. Financial details were not disclosed. “We consider antibodies to have the potential for outstanding efficacy in Read more about Schering, Philogen Agree License Deal[…]

ImClone Receives $3 Million Payment From Merck

ImClone Systems Incorporated has received a $3 million payment from Merck KGaA for achieving a clinical development milestone under the Companies’ license agreement for ERBITUX(TM). Upon payment, ImClone Systems issued 150,007 shares of ImClone Systems’ common stock to Merck KGaA, representing the sale of these shares at a ten percent premium to market value as Read more about ImClone Receives $3 Million Payment From Merck[…]

Demegen And Dow Form Development Collaboration

Demegen, Inc. and Dow Pharmaceutical Sciences have entered into a collaborative agreement to develop certain Demegen peptides into prescription pharmaceutical products. Under the terms of this agreement, Dow Pharmaceutical Sciences will be responsible for selecting suitable Demegen compounds for several topical disease indications; developing them and filing FDA applications; along with providing certain other services Read more about Demegen And Dow Form Development Collaboration[…]

Ligand, Lilly Agree Second Extension To R&D Collaboration

Ligand Pharmaceuticals and Eli Lilly and Company will extend until November 2004 their research collaboration focused on discovering novel drugs for type II diabetes and cardiovascular disorders. This represents the second extension of the collaboration with Lilly, and further strengthens both partners’ confidence in continued success going forward. The Lilly-Ligand collaboration, which began in 1997, Read more about Ligand, Lilly Agree Second Extension To R&D Collaboration[…]

A.I. Software Acquires Patented Stem Cell Expansion Technology

A.I. Software, Inc., has reached an agreement with the Weitzman Institute of Science and Technion — Israel Institute of Technology to acquire the exclusive rights of stem cell expansion technology. Researchers at Israel’s top research institutions have developed a unique advanced technology in its early stages that expands stem cells from umbilical cord blood without Read more about A.I. Software Acquires Patented Stem Cell Expansion Technology[…]

Geron And University Of California, Irvine Awarded BioSTAR Grant

Geron Corporation has announced the renewal of a matching grant from the University of California BioSTAR Project to support continued research on the use of human embryonic stem cells (hESCs) to derive oligodendrocytes for the treatment of spinal cord and related central nervous system (CNS) injuries. The work, originally initiated in August 2001 with Geron Read more about Geron And University Of California, Irvine Awarded BioSTAR Grant[…]